(thirdQuint)Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer.

 OBJECTIVES: - Assess the degree to which modafinil can reduce fatigue in cancer patients receiving chemotherapy.

 - Assess the relationship between depression and fatigue in patients treated with this drug.

 OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study.

 Patients are randomized to 1 of 2 treatment arms.

 - Arm I: Beginning on day 5 of the second course of chemotherapy, patients receive oral modafinil once daily.

 - Arm II: Beginning on day 5 of the second course of chemotherapy, patients receive oral placebo once daily.

 Treatment in both arms continues until day 7 of course 4 of chemotherapy in the absence of disease progression or unacceptable toxicity.

 Fatigue and quality of life are assessed on day 7 of courses 2-4 of chemotherapy.

 PROJECTED ACCRUAL: A total of 837 patients will be accrued for this study within approximately 2.

5 years.

.

 Modafinil in Treating Fatigue in Patients Receiving Chemotherapy for Cancer@highlight

RATIONALE: Modafinil may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy.

 The effectiveness of modafinil in relieving chemotherapy-related fatigue is not yet known.

 PURPOSE: This randomized phase III trial is studying the effectiveness of modafinil in treating fatigue in patients who are receiving chemotherapy for cancer.

